Publication: 3530

Phase IB Study of Sorafenib and Evofosfamide in Patients with Advanced Hepatocellular and Renal Cell Carcinomas (NCCTG N1153, Alliance)
      QxMD      Google Scholar   
Citation:
Invest New Drugs vol 39 (4) 1072-1080
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
10
Parents:
2486  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
Threshold Pharmaceuticals  
Grants:
U10CA180821, U10CA180882, UG1CA232760, DP2CA195764, K12CA090628  
Corr. Author:
 
Authors:
                   
Networks:
LAPS-MA036, LAPS-MN026, METROMIN   
Study
NCCTG-N1153
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1
Keywords:
Article